Bio-Rad Laboratories Inc Class A
BIO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$364.00 | Clnvl | Nljsnqy |
Narrow-Moat Bio-Rad Poised for Strong Year Driven by Sartorius Gains and Life Science Momentum
Narrow-Moat Bio-Rad reported strong second-quarter results, with currency-neutral sales growth of 27.5% and non-GAAP diluted EPS of $3.54 compared with EPS of $1.61 in second-quarter 2020. After adjusting our model for the strong near-term results and greater flow-through equity investment income from Sartorius, we are increasing our fair value estimate to $455 from $425. Our valuation increase is moderated by incorporating a weighted average U.S. tax rate of 26%.